http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102116870-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2563-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6851 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2018-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102116870-B1 |
| titleOfInvention | A method for providing prognosis in cervical cancer, and a kit therefor based reverse transcription real time PCR using p63 expression ratio |
| abstract | The present invention relates to a molecular diagnostic method and a kit using a p63 expression ratio that provides prognosis information for a patient with cervical cancer based on real-time reverse transcriptase polymerization, and the present invention rapidly utilizes a patient's tissue to generate a p63 gene of a patient's tumor The carcinogenic potential of (ΔNp63 expression level) and tumor suppression (TAp63 expression level) state can be derived through a single assay process, and the prognosis information of the patient can be confirmed according to the expression ratio. |
| priorityDate | 2018-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 63.